TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical DetectionMarketBeat • 08/18/26
TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock DownZacks Investment Research • 08/03/26
Here's What Key Metrics Tell Us About TG Therapeutics (TGTX) Q2 EarningsZacks Investment Research • 08/03/26
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue GuidanceGlobeNewsWire • 08/03/26
TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business UpdateGlobeNewsWire • 07/29/26
TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 07/27/26
TG Therapeutics Begins Phase II Study With Briumvi in SchizophreniaZacks Investment Research • 07/07/26
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant SchizophreniaGlobeNewsWire • 07/06/26
TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And ClimbingInvestors Business Daily • 06/17/26
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/11/26
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MGZacks Investment Research • 06/10/26
TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 TrialGlobeNewsWire • 06/09/26
Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?Zacks Investment Research • 06/05/26
TG Therapeutics: Phase 1 Results Of Subcutaneous Briumvi Are A De-Risking EventSeeking Alpha • 06/04/26